Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (321-330 of 740) with videos related to

Pageof 74
Sort By:
Hemasphere|March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 TrialKatja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
Hematological Oncology|March 28, 2023
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B diseaseFoteini Theodorakakou, Alexandros Briasoulis, Despina Fotiou, et al.
Ejhaem|January 27, 2025
Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myelomaEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Leukemia Research|September 29, 2009
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agentsEvangelos Terpos, Meletios A Dimopoulos, Vikas Shrivastava, et al.
International Journal of Cancer|November 5, 2011
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapyEvangelos Terpos, Dimitrios Christoulas, Eirini Katodritou, et al.
Leukemia & Lymphoma|November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparisonMaria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Viruses|April 23, 2022
Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek PatientsStavroula Labropoulou, Niki Vassilaki, Raphaela S Milona, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancerAmanda Psyrri, Aris Bamias, Ziwei Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factorsAristotle Bamias, Efstathios Kastritis, Christina Bamia, et al.
JAMA Oncology|September 24, 2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisSmith Giri, Alyssa Grimshaw, Susan Bal, et al.
Pageof 74

Showing results (321-330 of 740) with videos related to

Sort By:
Pageof 74
Hemasphere|March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 TrialKatja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
Hematological Oncology|March 28, 2023
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B diseaseFoteini Theodorakakou, Alexandros Briasoulis, Despina Fotiou, et al.
Ejhaem|January 27, 2025
Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myelomaEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, et al.
Leukemia Research|September 29, 2009
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agentsEvangelos Terpos, Meletios A Dimopoulos, Vikas Shrivastava, et al.
International Journal of Cancer|November 5, 2011
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapyEvangelos Terpos, Dimitrios Christoulas, Eirini Katodritou, et al.
Leukemia & Lymphoma|November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparisonMaria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Viruses|April 23, 2022
Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek PatientsStavroula Labropoulou, Niki Vassilaki, Raphaela S Milona, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancerAmanda Psyrri, Aris Bamias, Ziwei Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factorsAristotle Bamias, Efstathios Kastritis, Christina Bamia, et al.
JAMA Oncology|September 24, 2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisSmith Giri, Alyssa Grimshaw, Susan Bal, et al.
Pageof 74